Role of homocysteine for thromboembolic complication in patients with non-valvular atrial fibrilation

Basit Öğe Kaydı
dc.authorid0000-0002-2858-4023en_US
dc.authorid0000-0003-1407-5313en_US
dc.contributor.authorYiğiner, Ömer
dc.contributor.authorCebeci, Bekir Sıtkı
dc.contributor.authorKardeşoğlu, Ejder
dc.contributor.authorDemiralp, E.
dc.contributor.authorDinçtürk, Mehmet
dc.date.accessioned2024-07-12T21:02:09Z
dc.date.available2024-07-12T21:02:09Z
dc.date.issued2002en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractThromboembolism is the most important complication in patients with atrial fibrilation (AF). Homocysteine is a toxic amino acid that has been recently accepted as a risk factor for atherosclerosis and stroke. The aim of the present study is to show whether there is a relation between hyperhomocysteinemia and thromboembolic complications in patients with non-valvular AF. We admitted 38 patients with non-valvular AF. The patients were divided into two groups: group A (n = 20; mean age, 75.7 +/- 10.4 years; three males/17 females), and group B (n = 18; mean age, 68.0 +/- 10.6 years; 11 males/seven females). While group A consisted of the patients with AF and stroke, group B was composed of the patients with AF but without stroke. The patients having sinus rhythm (15 subjects) were used as the reference group to obtain the cut-off value. Homocysteine was measured by the immunoassay method. The means of the homocysteine levels were 12.4 +/- 3.3 micromol/l in group A, 8.3 +/- 2.3 micromol/l in group B and 9.3 +/- 1.8 micromol/l in the reference group. The cut-off value was 10.6 micromol/l. Group A had a statistically higher homocysteine level than not only group B, but also the reference group (P < 0.05). While 60% of group A (n = 12) had the elevated homocysteine level, the rate was only 22% for group B (n = 4). In conclusion, hyperhomocysteinemia may be one of the explanations for the increased rate of thromboembolic complications in older patients with AF.en_US
dc.identifier.citationCingozbay, B. Y., Yiginer, O., Cebeci, B. S., Kardesoglu, E., Demiralp, E. ve Dincturk, M. (2002). Role of homocysteine for thromboembolic complication in patients with non-valvular atrial fibrilation. Blood coagulation & fibrinolysis, Wolters Kluwer Health. 13(7), s. 609–613.en_US
dc.identifier.endpage613en_US
dc.identifier.issn0957-5235
dc.identifier.issn1473-5733
dc.identifier.issue7en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage609en_US
dc.identifier.urihttps://journals.lww.com/bloodcoagulation/Fulltext/2002/10000/Role_of_homocysteine_for_thromboembolic.5.aspx
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3587
dc.identifier.volume13en_US
dc.institutionauthorCingözbay, Bekir Yılmaz
dc.language.isoenen_US
dc.publisherWolters Klen_US
dc.relation.ispartofBlood Coagulation & Fibrinolysisen_US
dc.relation.isversionof10.1097/00001721-200210000-00005en_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsCC0 1.0 Universal*
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.snmzKY00433
dc.subjecthomocysteineen_US
dc.subjectthromboembolic complicationsen_US
dc.subjectatrial fibrilationen_US
dc.titleRole of homocysteine for thromboembolic complication in patients with non-valvular atrial fibrilationen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu